Tuberculosis remains one of the most consequential infectious disease challenges of our era, and this sweeping analysis arrives at a critical inflection point: as global health funding contracts, knowing precisely where the burden falls — and how far treatment and prevention have advanced — may determine whether the world stays on track for WHO's 2035 elimination targets or slides into a preventable reversal of decades of hard-won gains.
Drawing on the Global Burden of Disease Study 2023 framework, this systematic analysis quantifies TB mortality, morbidity, and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 through 2023. The researchers used an ensemble cause-of-death modeling platform integrating vital registration, surveillance, verbal autopsy, and minimally invasive tissue sampling, alongside DisMod-MR 2.1 for simultaneous incidence-prevalence-mortality modeling stratified by age, sex, HIV status, and drug-resistance profile. Population attributable fractions were calculated for major modifiable risk factors — alcohol use, smoking, and elevated fasting plasma glucose — providing a more granular picture of TB's intersecting drivers than prior GBD iterations. The scope specifically captures multidrug-resistant TB (MDR-TB) separately from drug-susceptible disease, a distinction critical for understanding treatment costs and outbreak risk.
The significance of this work extends well beyond surveillance bookkeeping. WHO's End TB Strategy demands a 95% reduction in TB deaths and a 90% decline in incidence by 2035 relative to 2015 baselines — trajectories this study allows researchers to test rigorously for the first time with 2023 data. The inclusion of HIV-stratified estimates is particularly important because HIV-TB co-infection carries mortality risks that dwarf those of either condition alone, yet treatment integration remains inconsistent across high-burden settings. The risk-factor PAF framework is analytically valuable, though observational in nature and subject to the confounding inherent in ecological attribution. For health-conscious adults in low-burden countries, the practical implication lies in understanding how metabolic risk factors — elevated blood glucose especially — interact with infectious disease vulnerability at a population level. This analysis is large-scale, methodologically rigorous, and likely to serve as a benchmark reference for TB policy through at least the next funding cycle.